Oklahoma Medical Research Foundation | Oklahoma City, OK
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Participants must have at least one of the following characteristics:
Participants must have an inadequate response or intolerance to at least 1 disease-modifying antirheumatic drugs (DMARD) (synthetic or biologic).
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
2,600 participants in 3 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal